Key Takeaways:
- DexCom’s new G7 15 Day continuous glucose monitoring (CGM) system has received FDA clearance for adults 18 and older with diabetes.
- The system lasts 15.5 days, longer than DexCom’s previous offerings, providing added convenience and reducing waste.
- With an 8% mean absolute relative difference (MARD), the G7 15 Day CGM is DexCom’s most accurate system yet.
- DexCom stock jumped nearly 10% on the news as the extended wear time puts competitive pressure on Abbott’s Libre CGM.
Introduction
DexCom Inc. (DXCM) saw its stock soar on Thursday after the medical device maker announced that its new continuous glucose monitoring (CGM) system had received clearance from the U.S. Food and Drug Administration (FDA). The key features of the newly approved DexCom G7 15 Day CGM include:
- Wear time extended to 15.5 days, significantly longer than previous DexCom CGM models
- Superior accuracy with an overall mean absolute relative difference (MARD) of 8%
- Intended for people aged 18 and older living with diabetes
Detailed Analysis
The FDA clearance marks a milestone for DexCom, with the G7 15 Day system setting “a new standard in CGM” according to Jake Leach, the company’s executive vice president and chief operating officer. Extended wear time has been a key area of focus for CGM manufacturers, as it enhances user convenience and reduces costs associated with frequently replacing sensors.
With its MARD of 8%, the G7 15 Day exceeds the accuracy of prior DexCom CGM generations, potentially giving it an edge over rivals like Abbott’s (ABT) FreeStyle Libre. As analysts at BTIG noted, “The 15-day wear period also puts G7 on more equal footing with Abbott’s Libre.”
In a Drug Topics article, Satish Garg, MD from the Barbara Davis Center for Diabetes described G7 15 Day as “the most accurate CGM for adults” based on data presented at a recent diabetes conference. The publication also highlighted how pharmacists can positively impact health outcomes for patients using CGM devices, including reductions in hemoglobin A1c levels 1.
Conclusion
With its newly cleared G7 15 Day CGM, DexCom has raised the bar for wearable glucose monitoring technology in terms of both wear time and accuracy. The product’s commercial launch in the second half of 2025 will put competitive pressure on rivals and could drive adoption among the massive diabetic patient population seeking more convenient ways to manage their condition.
While the extended sensor life stands to reduce costs for users, investors will be watching to see if the added manufacturing complexity impacts profit margins for DexCom. The company’s ability to maintain its pricing power amid intensifying competition in the CGM space will also be a key factor influencing the stock’s performance following its post-announcement rally.
References
1 Gallagher, Ashley (April 10, 2025). “FDA Clears New Dexcom G7 15 Day Continuous Glucose Monitoring System”. Drug Topics. Retrieved April 11, 2025.
2 DexCom G7 15 Day receives FDA clearance: The longest lasting wearable and most accurate CGM system (April 10, 2025). DexCom, Inc. News Release. Retrieved April 11, 2025.
3 Dexcom rises as FDA clears use of co’s 15-day continuous glucose monitor (April 10, 2025). TradingView News / Reuters. Retrieved April 11, 2025.
4 Halsey, Grace (April 10, 2025). “Dexcom G7 15 Day CGM System Cleared by FDA”. Patient Care Online. Retrieved April 11, 2025.
5 DexCom stock rises on FDA nod for new CGM (April 10, 2025). Seeking Alpha. Retrieved April 11, 2025.
